Healthy Volunteers
Conditions
Keywords
Hydromorphone, Opiates, Anti-doping control
Brief summary
Background: Hydromorphone (HM) is a semi-synthetic derivative of morphine used for pain control. Like other opiates, due to its high potential of abuse HM is included on the World Anti-Doping Agency (WADA) list of prohibited substances. Hypothesis: The oral administration of hydromorphone hydrochloride in healthy subjects allows generating detectable concentrations of the drug in urine. Positive urine samples will enable to identify analytical strategies for doping control. Objectives: Primary objective: To measure the concentrations of hydromorphone in urine for anti-doping control samples. Secondary objective: To identify metabolites and precursors of hydromorphone in urine. To assess safety and tolerability of the drug used. Methods: Phase I, open, non-randomized clinical trial, with a treatment condition (hydromorphone) administered orally to 2 subjects.
Detailed description
This study aims to characterize the patterns of urinary excretion of HM following the oral administration of 4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone). The detection of HM consumption can be done by urine immunoassay but several immunoassay tests are required to thoroughly detect synthetic, semi-synthetic and natural opioids due to the limited cross-reactivity of each assay. Therefore, superior test strategies are required to specifically identify low concentrations of opioids.
Interventions
4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
Sponsors
Parc de Salut Mar
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
There is one single treatment group (HM), and no control group.
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male volunteers aged between 18 and 45 years. * Able to understand and accept the trial procedures and able to sign an informed consent. * History and physical examination that demonstrate not presenting organic or psychiatric disorders. * ECG, blood and urine tests performed before the test within normal limits. Minor or occasional variations of these limits will be allowed if, in the opinion of the Principal Investigator and taking into account the state of science, they have no clinical significance, do not pose a risk to the subject and do not interfere in the product evaluation. These variations and their non-relevance will be specifically justified sin writing. * Body mass index (weight/height\^2) between 19 and 25 kg/m2. BMI between 25 and 27 kg/m2 may be included according to Principal Investigator's criteria.
Exclusion criteria
* History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance or similar nonapeptides, or to any of the excipients. * Patients who have undergone surgical interventions and/or have had underlying diseases that could lead to a stricture of the gastrointestinal tract, that have blind handles of the gastrointestinal tract or gastrointestinal obstruction. * Patients with severe decrease in liver function. * Patients with respiratory failure or history of asthma crisis. * Patients with acute abdominal pain of unknown origin. * Background or clinical evidence of gastrointestinal, hepatic, renal disorder or others that may involve an alteration of the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs. * Background or clinical evidence of psychiatric disorders, alcoholism, drug abuse or habitual consumption of psychoactive drugs. * Having participated in another clinical trial with medication in the three months prior to the start of the study. * Having suffered some organic disease or major surgery in the six months prior to the start of the study. * Antecedents or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological or other acute or chronic diseases that, in the opinion of the Principal Investigator or the collaborators designated by him/her, may pose a risk to the subjects or may interfere with the objectives of the study. Especially epileptic seizures or a history of epilepsy. * Having taken medication regularly in the month prior to the study sessions. Treatment with monoamine oxidase inhibitors (MAOIs), buprenorphine, nalbuphine or pentazocine during the two months prior to the study. Treatment with single doses of another type of symptomatic medication in the week prior to the study sessions will not be a reason for exclusion if it is assumed that the drug has been completely eliminated on the day of the experimental session. * Smokers of more than 20 cigarettes a day in the 3 months before the study. * Consumption of more than 20 g of alcohol daily in women and more than 40 g in men. * Consumers of more than 5 coffees, teas, cola drinks, or other stimulant drinks or with xanthines daily in the 3 months prior to the study start. * Being unable to understand the nature, consequences of the trial and the procedures that are asked to follow. * Positive serology for hepatitis B, C or HIV.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urine concentration of hydromorphone | 0-4 hours post-administration | Concentration of hydromorphone in fraction-1 urine samples |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urine concentration of hydromorphone metabolites | 0-4 hours post-administration | Concentration of different hydromorphone metabolites in fraction-1 urine samples |
Countries
Spain
Outcome results
None listed